Hormonal
In the context of Nonalcoholic Fatty Liver Disease (NAFLD), hepatic triglyceride accumulation acts as a hepatoprotective buffering mechanism against lipotoxicity; inhibiting triglyceride synthesis (e.g., via DGAT2 inhibition) exacerbates liver damage and fibrosis despite reducing steatosis.
If you have fatty liver, simply trying to 'burn off' liver fat without addressing the underlying insulin resistance and free fatty acid overflow might be counterproductive. The liver uses triglyceride storage as a safety buffer. Focus on reducing the influx of fatty acids (through caloric restriction and managing insulin resistance) rather than aggressive interventions that might disrupt this buffering capacity, as this can worsen liver inflammation and fibrosis.
Yamaguchi et al. [57] show that inhibiting triglyceride synthesis by inhibiting DAGT2 does improve hepatic steatosis, yet it exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Lipotoxicity arises when hepatic triglyceride synthesis is unable to accommodate increased free fatty acid accumulation. Thus, rather than being hepato-toxic, liver triglyceride accumulation is actually hepatoprotective in obese, insulin-resistant individuals.
Why this rating
The paper cites multiple experimental animal models (mouse knockouts, high-fat diets) and human metabolomic analyses, though it is a review of mechanisms rather than a single large-scale RCT.
Source
Nonalcoholic Fatty Liver Disease: Focus on Lipoprotein and Lipid Deregulation
Klementina Fon Tacer et al. · Journal of Lipids · 2011
DOI 10.1155/2011/783976
More from this paper
- Insulin resistance drives NAFLD pathogenesis through two main mechanisms: increased adipose tissue lipolysis (free fatty acid overflow) and increased hepatic de novo lipogenesis (fatty acid synthesis), leading to triglyceride accumulation.Strong
- Dietary cholesterol is a distinct and critical risk factor for the progression of NAFLD to NASH, driving inflammation and oxidative stress independently of total lipid accumulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →